Skip to main content
. Author manuscript; available in PMC: 2022 Mar 11.
Published in final edited form as: Cell Rep. 2021 Oct 12;37(2):109831. doi: 10.1016/j.celrep.2021.109831

Figure 1. Cck1R agonist A71623 treatment dampens Purkinje neuron pathology in ATXN1[30Q]D776;Cck−/− mice.

Figure 1.

(A) Scheme of assessment and treatment course. Mice were tested for motor performance using two tests. Then, either 0.02 mg/kg/day A71623 or vehicle (20 mM PBS) was administered until 36 weeks of age, at which time mice were sacrificed for pathology. Osmotic minipumps were replaced every 6 weeks.

(B) Time to cross the 10-mm round balance beam.

(C) Latency to fall on the rotarod.

(D) Molecular layer thickness in 36-week-old untreated and treated mice.

(E) Number of Purkinje neurons per 250 μm in cerebellar primary fissure in 36-week-old untreated and treated mice.

Error bars represent SEM. *p < 0.05, **p < 0.01, and ***p < 0.001, two-way ANOVA with Tukey post hoc test. N’s (B–E) are indicated within each bar on the graphs.